DelveInsight’s “Congenital Hyperinsulinism Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Congenital Hyperinsulinism market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Congenital Hyperinsulinism drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Congenital Hyperinsulinism treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Congenital Hyperinsulinism: An Overview
Congenital Hyperinsulinism (CHI) is a rare disease that causes newborns and children to have low blood sugar due to abnormal insulin release. It is the most common cause of persistent hypoglycemia in infants and children and carries a considerable risk of neurological damage and developmental delays if delayed diagnosis and treatment. It encompasses a heterogeneous group of rare β-cell disorders characterized by recurrent episodes of hyperinsulinemic hypoglycemia caused by dysregulated insulin secretion
Early symptoms of CHI can include jitteriness, poor feeding, lethargy, and a weak or high-pitched cry. These symptoms are frequently modest and non-specific. Apnea, seizures, extreme irritability, coma, or status epilepticus are more severe indicators of neuroglycopenia
Genetic CHI may be due to single gene mutations in the insulin secretory pathway or genes causing syndromes with multiple other associated factors (such as Beckwith–Wiedemann syndrome or Kabuki syndrome). Even though transient/acquired forms typically go away within a few days or weeks, up to one-third of children may experience aberrant neurodevelopment.
Congenital Hyperinsulinism Market Key Facts
-
The total market size of Congenital Hyperinsulinism in the United States accounted for USD 41.1 million in 2021.
-
In the EU5, the total market size of Congenital Hyperinsulinism was USD 51.3 million in 2021.
-
In Japan, the total market size of Congenital Hyperinsulinism was USD 10.7 million in 2021.
-
In the year 2021, the total diagnosed prevalent cases of Congenital Hyperinsulinism were 15,487 in the 7MM.
-
In the year 2021, the total number of diagnosed prevalent cases of Congenital Hyperinsulinism was 3,445 in the United States.
-
The highest number of total diagnosed prevalent cases of Congenital Hyperinsulinism was observed in Germany among the EU5 countries with 2,767 cases in 2021.
Congenital Hyperinsulinism Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Congenital Hyperinsulinism pipeline therapies. It also thoroughly assesses the Congenital Hyperinsulinism market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Congenital Hyperinsulinism drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Congenital Hyperinsulinism Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Congenital Hyperinsulinism epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Congenital Hyperinsulinism epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Congenital Hyperinsulinism Epidemiology, Segmented as –
-
Total diagnosed prevalent Cases of Congenital Hyperinsulinism (CHI) in the 7MM [2019–2032]
-
Total Treated Cases of Congenital Hyperinsulinism (CHI) in the 7MM [2019–2032]
-
Mutation specific diagnosed prevalence of Congenital Hyperinsulinism in the 7MM [2019–2032]
-
Type-specific diagnosed prevalence based on histological presentation in the 7MM [2019–2032]
Congenital Hyperinsulinism Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Congenital Hyperinsulinism market or expected to be launched during the study period. The analysis covers the Congenital Hyperinsulinism market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Congenital Hyperinsulinism drugs based on their sale and market share.
The report also covers the Congenital Hyperinsulinism pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Congenital Hyperinsulinism companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Congenital Hyperinsulinism Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market
Congenital Hyperinsulinism Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Congenital Hyperinsulinism. Currently, EIger Bio is leading the therapeutics market with its Congenital Hyperinsulinism drug candidates in the most advanced stage of clinical development.
Congenital Hyperinsulinism Companies Actively Working in the Therapeutics Market Include
-
Zealand Pharma
-
Rezolute
-
Hanmi Pharmaceutical
-
Crinetics Pharmaceuticals
And Many Others
Emerging and Marketed Congenital Hyperinsulinism Therapies Covered in the Report Include:
-
Avexitide: Eiger Bio
-
ZEGALOGUE (dasiglucagon): Zealand Pharma
-
RZ358: Rezolute
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Congenital Hyperinsulinism Competitive Intelligence Analysis
4. Congenital Hyperinsulinism Market Overview at a Glance
5. Congenital Hyperinsulinism Disease Background and Overview
6. Congenital Hyperinsulinism Patient Journey
7. Congenital Hyperinsulinism Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Congenital Hyperinsulinism Treatment Algorithm, Current Treatment, and Medical Practices
9. Congenital Hyperinsulinism Unmet Needs
10. Key Endpoints of Congenital Hyperinsulinism Treatment
11. Congenital Hyperinsulinism Marketed Therapies
12. Congenital Hyperinsulinism Emerging Drugs and Latest Therapeutic Advances
13. Congenital Hyperinsulinism Seven Major Market Analysis
14. Attribute Analysis
15. Congenital Hyperinsulinism Market Outlook (In US, EU5, and Japan)
16. Congenital Hyperinsulinism Companies Active in the Market
17. Congenital Hyperinsulinism Access and Reimbursement Overview
18. KOL Views on the Congenital Hyperinsulinism Market
19. Congenital Hyperinsulinism Market Drivers
20. Congenital Hyperinsulinism Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Degenerative Disc Disease (DDD) Market
“Degenerative Disc Disease (DDD) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Degenerative Disc Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Degenerative Disc Disease market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/